MarketPulse
A

$APGE

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Apogee Therapeutics to Unveil 52-Week Phase 2 Data for APG777 Atopic Dermatitis Treatment

Apogee Therapeutics to present 52-week Phase 2 data for APG777 in atopic dermatitis on March 23, 2026, signaling major clinical development milestone.
APGEbiologicsatopic dermatitis
The Motley FoolThe Motley Fool··Jonathan Ponciano

Great Point Partners Doubles Down on Apogee Therapeutics With $28M Position

Great Point Partners expands Apogee Therapeutics stake to $28.23M, now its largest holding. Stock doubled in value; Phase 2 atopic dermatitis data expected mid-2026.
APGEbiotechclinical trials